Long-acting injectable (LAI) antipsychotics, compared with oral antipsychotics (OA), have the potential to increase medication adherence in adult patients with schizophrenia. This increas...
Introduction: Schizophrenia (SCZ) is a severe mental disorder imposing substantial healthcare burden to society. Data quantifying the non-healthcare societal burden of SCZ is limited, esp...
Background: Antipsychotics with reduced dosing frequency may improve adherence and clinical outcomes for patients with schizophrenia. This study compared adherence, persistence, healthcar...
Long-acting injectable (LAI) antipsychotics are recommended by clinical guidelines for patients with schizophrenia who struggle with adherence and/or recurrent relapses. However, LAI util...
BACKGROUND: Schizophrenia relapses can cause a significant increase in healthcare resource utilization and costs. However, the risk of relapse may be different between patients initiated ...
Background: Schizophrenia carries a substantial economic burden to healthcare systems and payers. This study aims to update the prevalence, incidence and economic burden of schizophrenia ...
Objective: Limited data are available on patient characteristics and healthcare burden of schizophrenia in a healthcare system. This analysis examined the characteristics and healthcare b...
BACKGROUND: Data on the burden associated with schizophrenia relapse within the new treatment landscape is scarce. This study aims to identify relapse in schizophrenia and update their as...
Objective: A previous study demonstrated that patients with schizophrenia consumed substantial healthcare resources in an integrated healthcare system. This study evaluated healthcare uti...